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Background: The aim of this study was to assess if FDG-PET could guide dose prescription heterogeneity and
decrease arbitrary location of hotspots in SBRT.
Methods: For three patients with stage I lung cancer, a CT-simulation and a FDG-PET were registered to define
respectively the PTVCT and the biological target volume (BTV). Two plans involving volumetric modulated arc therapy
(VMAT) and simultaneous integrated boost (SIB) were calculated. The first plan delivered 4 × 12 Gy within the PTVCT
and the second plan, with SIB, 4 × 12 Gy and 13.8 Gy (115% of the prescribed dose) within the PTVCT and the BTV
respectively. The Dmax-PTVCT had to be inferior to 60 Gy (125% of the prescribed dose). Plans were evaluated through
the D95%, D99% and Dmax-PTVCT, the D2 cm, the R50% and R100% and the dice similarity coefficient (DSC) between
the isodose 115% and BTV. DSC allows verifying the location of the 115% isodose (ideal value = 1).
Results: The mean PTVCT and BTV were 36.7 (±12.5) and 6.5 (±2.2) cm
3 respectively. Both plans led to similar target
coverage, same doses to the OARs and equivalent fall-off of the dose outside the PTVCT. On the other hand, the location
of hotspots, evaluated through the DSC, was improved for the SIB plans with a mean DSC of 0.31 and 0.45 for the first
and the second plans respectively.
Conclusions: Use of PET to decrease arbitrary location of hotspots is feasible with VMAT and SIB for lung cancer.
Keywords: Stereotactic body radiation therapy, Lung cancer, Positron emission tomography, Volumetric modulated
arc therapyIntroduction
Stereotactic body radiation therapy (SBRT) is considered
as a standard treatment for patients with inoperable
early stage lung cancer and leads to local control rates
over 90% [1-4]. Historically, SBRT is delivered using a
large number of non-overlapping treatment beams or
arcs to create a sharper dose gradient between the target
volume and the surrounding normal tissues. These delivery
techniques result in large dose heterogeneity with a
frequent dose prescription specified at the 80% (or lower)* Correspondence: b.henriques@bordeaux.unicancer.fr
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ume (PTV). The recent ROSEL guidelines about SBRT
recommend the maximum PTV dose to be between 110%
and 140% of the prescription dose [5]. However, the
location of these hotspots within the PTV is uncer-
tain and uncontrolled by conventional SBRT delivery
techniques.
Recent developments including volumetric modulated
arc therapy (VMAT) with one or multiple arcs and
varying openings of the multi-leaf collimator (MLC),
dose rates and gantry speed, have resulted in more
homogeneous dose distributions in SBRT [6]. However,
clinical results of SBRT have historically been obtained
with overdoses ranging from 120 to 140% inside the PTV,e BioMed Central. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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to delivering more homogeneous treatments, if used
with simultaneous integrated boost (SIB), VMAT can
also create a dose heterogeneity and controlled hotspots
inside the PTV.
For non-small cell lung cancers (NSCLC), positron
emission tomography (PET) with [18F]-Fluorodeoxyglucose
(FDG) is frequently used to optimize radiotherapy for
advanced stages with a better distinction between tumour
and atelectasis, and a better detection of involved nodes.
PET is not used for SBRT planning because the definition
of the gross tumor volume (GTV) on computed tomog-
raphy (CT) imaging in NSCLC stage I cases is not difficult.
However, several studies have shown that FDG-PET could
detect the sites at risk of failure inside GTV [7,8]. These
observations led us to use FDG-PET to guide hotspots
and dose prescription heterogeneity for NSCLC SBRT
with VMAT.
For this purpose, a feasibility study was conducted by
analyzing the dosimetries of three patients. For each
patient, two VMAT plans were performed and com-
pared: the first plan delivered SBRT using only CT data,
whereas the second plan delivered SBRT using CT and
FDG-PET data to guide dose prescription heterogeneity.
Material and methods
Patient group
Three patients, enrolled in a clinical trial assessing the
impact of 4D-FDG-PET in radiotherapy for lung cancer,
were selected for this dosimetric study. The study was
approved by the institutional review board of the universi-
tary hospital and the French health authority and patients
gave written informed consent to participate. All patients
were male with a median age of 70 years [62–72] and per-
ipheral T1N0M0 NSCLC (two adenocarcinomas and one
squamous cell carcinoma). The tumour was located in the
left inferior lobe with attachment to the chest wall for pa-
tient 1, in the middle lobe for patient 2, and in the left
upper lobe for patient 3.
Imaging
For CT simulation, patients were in supine position with
the arms above the head using an armrest. Data were
acquired with a 3-mm slice in free breathing. No four
dimensional (4D) acquisition was performed because
4D CT scan was not implemented in our department at
the date of this study. For FDG-PET/CT, a 4D acquisition
was performed in radiotherapy treatment position, 50 min
after intravenously injection of 3.7 MBq/Kg of [18F]-FDG,
on a PET/CT integrated system (Discovery RX, General
Electric Medical System®, Milwaukee, WI) using the
Real-time Position Management (RPM) device (Varian®)
and the “Motion Free” software (General Electric Medical
System®). The respiratory cycle was rebinned in six phases.Target volumes definition
For the target volume definition, CT simulation and PET/
CT were registered using a rigid algorithm. The GTVCT
was delineated manually on CT simulation using a paren-
chymal window (−1000 and +200 Hounsfield Units).
Patients 1 and 3 presented a non-mobile lesion (located in
the upper lobe or attached to the chest), therefore a 5 mm
isotropic margin was added to GTV to create PTVCT. For
patient 2, a 8 mm isotropic margin was added.
The Biological Target Volume (BTV) was defined on
4D-PET and corresponded to the sum of the six BTV
delineated on the six respiratory-gated PET images. BTV
was delineated on each PET image using the fuzzy locally
adaptive Bayesian (FLAB) method (9), which is an
automatic segmentation method. This statistic algorithm
combined with a fuzzy measure is particularly adapted to
noisy and blurry PET images, and has been validated on
both simulated and clinical datasets for accuracy and
robustness. Also, BTV included internal target volume
(ITV) in its definition.
The lung-PTV, spinal cord, oesophagus, heart, trachea,
brachial plexus and chest wall were outlined as organs at
risk (OAR) on CT simulation.
Dose prescription and treatment planning
For each patient, two RapidArc plans (Varian Medical
System®) were calculated by the same radiophysicist
using the Eclipse treatment planning software (Helios,
Varian Medical System®) with the Analytic Anisotropic
Algorithm v.10. For the first plan, the objective was to
deliver 48 Gy in PTVCT in 4 fractions of 12 Gy. For the
second plan, the objective was to deliver 48 Gy in
PTVCT and to guide hotspots in BTV with SIB. Both
plans adopted the following ROSEL recommendations:
95% of the PTVCT had to receive at least 100% of the
prescribed dose and 99% of the PTVCT at least 90% of
the prescribed dose. The maximum dose within the
PTVCT (Dmax PTVCT) had to be lower than 125% of
the prescribed dose. Additional constraints included
the D2cm (maximal dose at 2 cm of the PTVCT), the
R50% and R100% (ratios between PTVCT and the 50%
and 100% isodoses, respectively) allowing to verify the
rapid fall-off of the dose outside the PTVCT. The OARs
dose constraints were in accordance with the RTOG 0915
trial. The Dmax of the spinal cord, the brachial plexus, the
oesophagus, the heart and the trachea were inferior to 26,
27.2, 30, 34 and 34.8 Gy, respectively. For the chest wall,
the dose to one cm3 (D1cc) was kept below 32Gy.
RapidArc plans were performed with three 180° coplanar
arcs using 6MV photons at a maximum dose rate of 600
monitor units (MUs) per minute. Collimator angles of 15,
30 and 330° were used to minimize the tongue-and-groove
effect. For the first plan, 12 Gy per fraction were prescribed
at the barycentre of the PTVCT. For the second plan, 12 Gy
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with SIB in PTVCT and BTV, respectively.
Dosimetric analysis
In order to assess hotspots, we calculated the volume of the
115% isodose (Viso115%) and the Dice Similarity Coefficient
(DSC). DSC allows to verify the location of the 115% iso-
dose, and was defined as follows: DSC = (Viso115%∩VBTV)/
(Viso115%∪VBTV). Ideally, DSC is equal to 1.
Results
The mean PTVCT and BTV were 36.7 (±12.5) and
6.5 (±2.2) cm3, respectively. For both plans, ROSEL
recommendations were respected. The SIB technique
(plan 2) led to similar target coverage than that obtained
with conventional prescription on PTVCT (plan 1): the
mean D95%, D99% and the Dmax of the PTVCT were
103.7% ± 1.3, 101.6% ± 2.1 and 123.5% ± 1.9 without SIB,
versus 103.7% ± 2.4, 101.3% ± 2.1 and 124.4% ± 0.3 with
SIB. The rapid fall-off of the dose outside the PTVCT
was equivalent for both plans: the mean D2cm, R50%
and R100% were 62.4% ± 3.9, 4.6% ± 0.7 and 1.1% ± 0.08
without SIB, versus 66.2% ± 3.9, 4.7% ± 0.9 and 1.09% ± 0.1
with SIB.
For both plans, constraints of doses to the OARs were
respected, except for the dose to the chest wall for patient
1, who presented a tumour attached to the rib.
To assess the ability of the SIB to guide hotspots,
we evaluated the volume of the 115% isodose and the
location of this isodose through the analysis of the
DSC (Table 1). The Viso115% was more important in
plan 2, with a 33% and 16% increase for patients 1
and 3, respectively. On the contrary, for patient 2 the
Viso115% was bigger in the plan 1 with a difference
of 85%. Analysis on the location of the 115% isodose
revealed that SIB technique improves DSC with a mean of
0.31 for plan 1 and 0.45 for plan 2.. SIB technique’s ability
to guide hotspots in the BTV and to decrease arbitrary
hotspots is illustrated in Figure 1.
Discussion
One limitation of this study is the lack of 4D-CT simula-
tion, which impedes a good estimation of the ITV. An iso-
tropic margin was also added automatically around theTable 1 The 115% isodose and the dice similarity
coefficient (DSC)
Patient Viso115% (cm3) DSC BTV-Viso115% (%)
Plan 1 Plan 2-SIB Plan 1 Plan 2-SIB
1 14 18.6 0.26 0.45
2 22.2 12 0.21 0.4
3 10 11.6 0.45 0.51
Mean (± SD) 15.4 ± 6.2 14.1 ± 3.9 0.31 ± 0.13 0.45 ± 0.06GTVCT, probably leading to an overestimation of the
PTVCT. The present investigation, however, does not
focus on target volume definition, but rather on the use of
PET and VMAT to control and guide hotspots in SBRT.
In this respect, the study demonstrates that it is feasible to
guide dose prescription heterogeneity on FDG-PET
data with VMAT and SIB. Indeed, plans 1 and 2
respected conventional dosimetric criteria of SBRT
equally (D95% PTVCT, 99% PTVCT, Dmax PTVCT,
D2cm, R50% and R100%) and imparted equivalent
doses to the OARs. In contrast, better DSC was com-
puted with plan 2. In this study, we chose to perform
a SIB with a dose of 115% of the prescribed dose, because
the BTV defined on 4D-FDG-PET is relatively large con-
sidering the ITV. FDG-PET was used because its ability to
detect sites of relapse after radiotherapy is recognized.
After conventional fractionated radiotherapy treatments,
relapses are often located inside the area of highest uptake
on baseline FDG-PET scan [7,8]. That’s why some authors
try to increase the radiation dose inside this BTV. Our
purpose was based on this idea and was to integrate data
of FDG-PET in SBRT focusing hotspots on BTV. Other
PET tracers like hypoxia or proliferation tracers could be
of interest to individualize more specific BTVs. These
BTVs issued from more specific tracers are often smaller
than those defined with FDG. The choice of isodose
(115, 120% or higher) to focus hotspots could also
vary depending on the tracer and volume of BTV.
Whatever the choice of the tracer, an important diffi-
culty stays the choice of the method of PET images
segmentation. Many automatic segmentation methods
are described in the literature and in the absence of a
confrontation with gold standards or surgical specimens,
it’s impossible to promote one method. More complex
segmentation methods as gradient based or stochastic
methods seem more robust than thresholding methods
based on SUV [9,10].
VMAT is particularly interesting to plan and deliver
SBRT. The number of studies concerned with SBRT and
VMAT has incredibly increased these last years. Several
dosimetric comparisons confirmed an important re-
duction in treatment time compared to other delivery
techniques like three-dimensional conformal radio-
therapy, Cyberknife or Tomotherapy [6,11-14] as well
as a reduction of patient movements caused by dis-
comfort and a reduction of the consecutive intra-
fraction motion. VMAT can achieve better conformity,
sharper dose fall-off outside the PTV and lower dose
to normal lung [12-15].
However, concerns about use of modulation therapy
for SBRT for tumors subject to respiratory motion have
been previously highlighted with the “interplay effect”
[16]. This effect describes the interplay between MLC
motion and tumour motion with risk of hotspots or cold
Figure 1 Comparison of both plans for the three patients: plans 1 in (A) and (B) and plans 2 with SIB in (C) and (D). PTVCT is shown in
blue and BTV in yellow. With both techniques, the target coverage of the PTVCT with the 100% isodose is adequate but the 115% isodose is more
focused on the BTV with the SIB technique.
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the impact of tumour motion on 4D dose calculation for
lung SBRT and found a negligible interplay effect, with
differences between 3D and 4D calculations around 1%
[17,18]. Several reasons may explain this negligible effect.
First, since high doses per fraction are delivered during
SBRT, most VMAT segments receive a large number of
MUs with a long segment delivery time (on the order of the
breathing period). Moreover, modulation for lung SBRT is
low with few OARs. Also, most segments contain an aper-
ture shape conformed to the PTV and few segments have
leaves blocking a part of the tumor. In the same way,
the gantry speed is in general low to be able to de-
liver a large number of MUs at each segment. Few
clinical studies about modulation intensity for lung
SBRT are published but results of the Mayo clinicwith IMRT [19], of Yamashita et al. [20] with VMAT
or Navarria et al. [15] with VMAT unflattened beams
(FFF) are good with excellent local control.Conclusion
Use of PET to guide dose prescription heterogeneity
with VMAT and SIB for lung cancer is feasible and
seems promising. These preliminary results have to
be confirmed with more patients and confronted to
a clinical study. Moreover, other PET tracers more
specific than FDG could be evaluated for this dose
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